The High Cost of Hope: Gene Therapy for Rare Diseases
Von Maxim Sharakin In recent years, a transformative shift has occurred in the landscape of therapy approval for rare diseases, with regulatory bodies increasingly favoring the entry of novel treatments to be fast in reaching patients in need. This departure from the conventional gold standard trial, where one group of patients receives the treatment and […]